Galapagos increases share capital through warrant exercises, receives transparency notifications

Mechelen, Belgium; 28 June 2010 – Galapagos NV (Euronext: GLPG) announced today a €0.35 million capital increase arising from employee warrant exercises.  Galapagos also announced that it has received transparency notifications from Apax and Gestion, pursuant to the Belgian transparency legislation (Belgian Act of 2 May 2007) concerning major holdings in Belgian listed companies.


Share capital increase
Since its inception in 1999, Galapagos has used warrant plans to incentivize personnel and management and have them share in the success of the company.  Following warrant exercises during the exercise period in June 2010, Galapagos issued 40,160 new ordinary shares on 28 June 2010 for a total capital increase, including share premium, of €349,831.11, or an average of €8.71 per new share.  No member of the Board or Executive Committee exercised warrants.  Following today’s capital increase, Galapagos now has a share capital amounting to €129,233,772.58, with a total of 23,890,038 ordinary shares outstanding.  There are no other voting securities.


Transparency information
Following on the announcement of a successful private placement on 17 June 2010, Galapagos received a transparency notification on 24 June 2010 that Altamir Amboise SCA, and Apax Partners SA acting as manager of FCPR Apax France, sold a combined total of 1,277,366 shares in the Company, reducing their combined holding to zero shares. 


Galapagos received a transparency notification on 28 June 2010 indicating that Mr. A. Strating, TWE Beheer, TWE Investment, and Gestion Deelnemingen V currently hold a combined 1,252,550 shares (5.25%); this represents an increase from the 1,184,692 shares (5.02%) previously notified by Gestion Deelnemingen V.


About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action.  The Company is progressing one of the largest pipelines in biotech, with four clinical and over 50 small molecule discovery/pre-clinical programs.  Through risk/reward-sharing alliances with GlaxoSmithKline, Eli Lilly, Janssen Pharmaceutica, Merck & Co. and Roche, Galapagos is eligible to receive up to €3 billion in downstream milestones, plus royalties.  Together with its BioFocus and Argenta service operations, Galapagos has over 670 employees and operates facilities in six countries, with global headquarters in Mechelen, Belgium.  More info at:




Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028


Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240



This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.